Jon Northam, MD
Obstetrics & Gynecology · Texarkana, TXNPI 1831190610
Payments from drug & device makers
Across 85 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$372
- Astellas Pharma US Inc$311
- Pfizer$181
- Sumitomo Pharma America, Inc.$148
- Myovant Sciences Inc.$118
- Biogen$83
- plus $364 from 15 others
What the payments were for
- Consulting fees$191%
- Food & beverage$1,46593%
- Education$946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $372 |
| Astellas Pharma US Inc | 14 | $311 |
| Pfizer | 11 | $181 |
| Sumitomo Pharma America, Inc. | 8 | $148 |
| Myovant Sciences Inc. | 7 | $118 |
| Biogen | 4 | $83 |
| Amgen | 5 | $79 |
| Pacira Pharmaceuticals Incorporated | 3 | $44 |
| Exact Sciences | 2 | $42 |
| Scynexis, Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Coopersurgical, Inc. | 1 | $19 |
| Organon | 1 | $17 |
| Merck | 1 | $16 |
| Vertex | 1 | $16 |
| Channel Medsystems, Inc. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$1,577 in reported general payments places this provider in the 60th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 93 | $4,775 |
| ValacyclovirValacyclovir Hcl | 28 | $661 |
| Raloxifene Hcl | 12 | $540 |
| Alendronate Sodium | 19 | $345 |
| Terconazole | 13 | $344 |
| Fluconazole | 45 | $341 |
| Clobetasol Propionate | 17 | $230 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 22 | $214 |
| Escitalopram Oxalate | 12 | $85 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Texarkana
- Amir JazaeriHouston$19.5M
- Shannon WestinHouston$17.3M
- Monica LopezFort Worth$8.1M
- Cynthia RobbinsFort Worth$7.8M
- John Paul RobertsPlano$4.9M
- Stephen StamatisWeatherford$4.5M
- Parke HedgesSan Antonio$4.2M
- Mary MartinBeaumont$2.8M
- Mark JacobsHouston$2.8M
- Dawnette PepplerArlington$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.